{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:40:45Z","timestamp":1761507645987,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.prrv.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:33:18Z","timestamp":1684171998000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Editorial: Optimism grows after 10\u00a0years of modulator therapies in Cystic Fibrosis"],"prefix":"10.1016","volume":"46","author":[{"given":"Dominic A.","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.prrv.2023.05.004_b0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2023.05.004_b0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s41030-021-00158-5","article-title":"Real-world long-term ivacaftor for cystic fibrosis in France: clinical effectiveness and healthcare resource utilization","volume":"7","author":"Hubert","year":"2021","journal-title":"Pulm Ther"},{"issue":"155","key":"10.1016\/j.prrv.2023.05.004_b0015","doi-asserted-by":"crossref","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"journal-title":"ERJ Open Res","year":"2022","author":"Muilwijk","key":"10.1016\/j.prrv.2023.05.004_b0020"},{"issue":"5","key":"10.1016\/j.prrv.2023.05.004_b0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.prrv.2023.05.004_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.chest.2021.06.018","article-title":"Counterpoint: In the era of cystic fibrosis transmembrane regulator protein modulator therapy, are the treatment goals for adults now different from those for children with cystic fibrosis? No","volume":"161","author":"Thursfield","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2023.05.004_b0035","first-page":"35","article-title":"Left behind: the potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis","volume":"42","author":"McGarry","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s41030-021-00170-9","article-title":"CFTR modulator therapy and its impact on lung transplantation in cystic fibrosis","volume":"7","author":"Benden","year":"2021","journal-title":"Pulm Ther"},{"key":"10.1016\/j.prrv.2023.05.004_b0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12890-022-01825-2","article-title":"Lived experiences of individuals with cystic fibrosis on CFTR-modulators","volume":"22","author":"Page","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.prrv.2023.05.004_b0050","article-title":"The psychological implications and health risks of cystic fibrosis pre-and post-CFTR modulator therapy","volume":"3","author":"Keyte","year":"2022","journal-title":"Chronic Illn"},{"key":"10.1016\/j.prrv.2023.05.004_b0055","first-page":"1","article-title":"Mini-symposium: Cystic fibrosis in the era of modulators (Part 1)","volume":"46","author":"Fitzgerald","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0060","first-page":"3","article-title":"CFTR modulator therapies\u2013Effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0065","first-page":"9","article-title":"Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators","volume":"42","author":"Konrad","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0070","first-page":"17","article-title":"Does newborn screening improve early lung function in cystic fibrosis?","volume":"42","author":"Davies","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0075","first-page":"23","article-title":"Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?","volume":"42","author":"Dixon","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0080","first-page":"29","article-title":"Revisiting a diagnosis of cystic fibrosis\u2013Uncertainties and considerations","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0085","first-page":"23","article-title":"Cystic fibrosis-related diabetes: clinical approach and knowledge gaps","volume":"46","author":"Prentice","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0090","first-page":"S1526","article-title":"Cystic fibrosis related diabetes (CFRD) in the era of modulators: A scoping review","volume":"5","author":"Prentice","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0095","first-page":"12","article-title":"Sleep in children and young adults with cystic fibrosis","volume":"46","author":"Fauroux","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0100","first-page":"17","article-title":"Approaches to the management of haemoptysis in young people with cystic fibrosis","volume":"46","author":"Sheppard","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2023.05.004_b0105","first-page":"30","article-title":"Psychosocial needs and interventions for young children with Cystic Fibrosis and their families","volume":"46","author":"Li","year":"2023","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.prrv.2023.05.004_b0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:37:20Z","timestamp":1761507440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054223000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"alternative-id":["S1526054223000234"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2023.05.004","relation":{},"ISSN":["1526-0542"],"issn-type":[{"type":"print","value":"1526-0542"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial: Optimism grows after 10\u00a0years of modulator therapies in Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}